Panbela Therapeutics, Inc. financial data

Symbol
PBLA on OTC
Industry
Pharmaceutical Preparations
Location
712 Vista Blvd #305, Waconia, MN
State of incorporation
DE
Fiscal year end
December 31
Former names
Sun BioPharma, Inc. (to 12/2/2020), Cimarron Medical, Inc. (to 9/4/2015), CIMARRON SOFTWARE INC (to 5/26/2015)
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 18.1 % -70%
Debt-to-equity -201 % +88.3%
Return On Equity 305 % -89.6%
Return On Assets -302 % -66%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4.85M shares -5.32%
Common Stock, Shares, Outstanding 4.85M shares +62%
Entity Public Float 6M USD -47.5%
Common Stock, Value, Issued 5K USD +66.7%
Weighted Average Number of Shares Outstanding, Basic 4.85M shares +3232%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 24.7M USD +37.5%
General and Administrative Expense 4.35M USD -24.9%
Operating Income (Loss) -29.1M USD -22.3%
Nonoperating Income (Expense) 983K USD +1265%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -28.1M USD -18.5%
Income Tax Expense (Benefit) -158K USD +11.7%
Net Income (Loss) Attributable to Parent -27.9M USD -18.7%
Earnings Per Share, Basic 284 USD/shares +97.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 142K USD -84.3%
Assets, Current 5.17M USD +174%
Other Assets, Noncurrent 0 USD -100%
Assets 5.17M USD -51.4%
Accounts Payable, Current 11M USD +65.6%
Accrued Liabilities, Current 5.47M USD +383%
Liabilities, Current 20.1M USD +126%
Liabilities 23.3M USD +78%
Accumulated Other Comprehensive Income (Loss), Net of Tax 541K USD -60.5%
Retained Earnings (Accumulated Deficit) -147M USD -5.1%
Stockholders' Equity Attributable to Parent -18.2M USD -632%
Liabilities and Equity 5.17M USD -51.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -9.39M USD +3.68%
Net Cash Provided by (Used in) Financing Activities 7.08M USD -48.3%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 4.85M shares +62%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.32M USD -159%
Interest Paid, Excluding Capitalized Interest, Operating Activities 266K USD -31.1%
Deferred Tax Assets, Valuation Allowance 26.3M USD +20.6%
Deferred Tax Assets, Gross 26.3M USD +20.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -28.7M USD -22.3%
Deferred Tax Assets, Operating Loss Carryforwards 18.5M USD +5.26%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 128M USD +20.9%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 103K USD -42.8%
Interest Expense 278K USD -28.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%